Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer

NCT06366490 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer
Recurrent Epithelial Ovarian Cancer Which Includes Epithelial Ovarian, Fallopian Tube and/or Primary Peritoneal Cancer

Interventions

BIOLOGICAL: Innocell Autologous Cellular Immunotherapy

Sponsor

PhotonPharma, Inc.